Stay informed with the latest litigation news. Explore now

IP Verse

Miltenyi patent opposition analysis

Latest oppositions filed by Miltenyi

Explore patent oppositions filed by Miltenyi against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Last updated on: Sep 4, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3696277
Quantitative Dna-Based Imaging And Super-Resolution ImagingPRESIDENT AND FELLOWS OF HARVARD COLLEGESep 8, 2023
EP3247808
Point-Of-Care And/Or Portable Platform For Gene TherapyFRED HUTCHINSON CANCER RESEARCH CENTERFeb 1, 2022
EP3237442
CellAUTOLUSApr 8, 2020
EP3214091
Use Of Chimeric Antigen Receptor-Modified T Cells To Treat CancerTHE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAJul 2, 2019
EP2734538
Method Of Reversibly Staining A Target CellIBAFeb 1, 2019
EP2364480
Substance Monitoring And Control In Human Or Animal BodiesCAMBRIDGE ENTERPRISEDec 7, 2018
EP2782997
Scalable Lentiviral Vector Production System Compatible With Industrial Pharmaceutical ApplicationsGENETHONOct 9, 2018
EP2651978
Use Of An Antibody Directed Against A Membrane ProteinLABORATOIRE FRANAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESFeb 9, 2018

Latest patents of Miltenyi opposed by its competitors

Explore Miltenyi's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 4, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3134512
Jan 2, 2019Method For Automated Generation Of Genetically Modified T Cells3
EP3025719
Sep 26, 2018Combination Immunotherapy Of Antigen-Recognizing Receptors And Hematopoietic Cells For The Treatment Of Diseases1

Top competitors of Miltenyi

Top competitors of Miltenyi based on patent oppositions.